Most eczema treatments are built to fight one thing at a time, either the visible flare-ups or the itch that comes with them. A new injectable antibody is designed to go after both simultaneously, and early trial data suggest that the dual approach might pay off.
As reported by Dermatology Times, researchers shared preliminary phase 1 trial results for BBT001, an antibody designed to block two inflammatory pathways involved in eczema at once. Patients treated with the drug saw significant skin clearing within just one week, and itch relief starting as early as the day after their first dose.
How Fast Is Fast?
By week six, patients on BBT001 saw dramatic improvement in skin clearing compared with placebo. Itch relief was even more striking. It remained noticeable for up to eight weeks after patients’ last dose, well beyond the treatment period itself.
What Dermatologists Are Saying
New York dermatologist Michael Cameron, MD, a lead investigator on the study, said the results stood out. “The speed, depth and consistency of clinical improvement observed with BBT001 exceeded my expectations, particularly given the short treatment duration and severity of disease among the participants,” Dr. Cameron said. “I am grateful to our patients and proud that our site contributed to the advancement of a potential novel therapy that, if approved, could reshape the treatment landscape for AD.”
Fewer Shots, Same Relief?
Portland, OR dermatologist Eric Simpson, MD, pointed to another advantage: the drug’s long half-life may eventually allow for dosing as infrequently as once every three months, putting it in line with other pipeline treatments aiming to cut down on frequent injections. “Despite important advances in AD treatment, patients and physicians are still looking for therapies that provide more complete control of both skin lesions and itch without the burden of frequent dosing,” Simpson said.
The treatment was reported to be well tolerated, with no cases of eye irritation, a side effect sometimes seen with other eczema biologics.
What This Means for You
This is still a small, early-stage study, just 17 patients, so larger trials will be needed to confirm these results. But for people who deal with eczema’s relentless itch, a treatment that works fast and keeps working long after the last dose is promising.
